Literature DB >> 28197360

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.

Jonathan M Pitt1, Marie Vétizou1, Ivo Gomperts Boneca2, Patricia Lepage3, Mathias Chamaillard4, Laurence Zitvogel5.   

Abstract

Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.

Entities:  

Keywords:  Anti-CTLA-4; Bacteroides; T cell; cancer; ipilimumab; microbiome; microbiota

Year:  2016        PMID： 28197360      PMCID： PMC5283646          DOI： 10.1080/2162402X.2015.1132137

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  A new vision of immunity: homeostasis of the superorganism.

Authors:  G Eberl
Journal:  Mucosal Immunol       Date:  2010-05-05       Impact factor: 7.313

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 4.  Cancer and the gut microbiota: an unexpected link.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Sophie Viaud; Marie Vétizou; Romain Daillère; Miriam Merad; Guido Kroemer
Journal:  Sci Transl Med       Date:  2015-01-21       Impact factor: 17.956

5.  Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms.

Authors:  Suryasarathi Dasgupta; Deniz Erturk-Hasdemir; Javier Ochoa-Reparaz; Hans-Christian Reinecker; Dennis L Kasper
Journal:  Cell Host Microbe       Date:  2014-04-09       Impact factor: 21.023

6.  Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Authors:  Noriho Iida; Amiran Dzutsev; C Andrew Stewart; Loretta Smith; Nicolas Bouladoux; Rebecca A Weingarten; Daniel A Molina; Rosalba Salcedo; Timothy Back; Sarah Cramer; Ren-Ming Dai; Hiu Kiu; Marco Cardone; Shruti Naik; Anil K Patri; Ena Wang; Francesco M Marincola; Karen M Frank; Yasmine Belkaid; Giorgio Trinchieri; Romina S Goldszmid
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

7.  The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Authors:  Sophie Viaud; Fabiana Saccheri; Grégoire Mignot; Takahiro Yamazaki; Romain Daillère; Dalil Hannani; David P Enot; Christina Pfirschke; Camilla Engblom; Mikael J Pittet; Andreas Schlitzer; Florent Ginhoux; Lionel Apetoh; Elisabeth Chachaty; Paul-Louis Woerther; Gérard Eberl; Marion Bérard; Chantal Ecobichon; Dominique Clermont; Chantal Bizet; Valérie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Paule Opolon; Nadia Yessaad; Eric Vivier; Bernhard Ryffel; Charles O Elson; Joël Doré; Guido Kroemer; Patricia Lepage; Ivo Gomperts Boneca; François Ghiringhelli; Laurence Zitvogel
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

8.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors:  Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728
  9 in total
  15 in total

1.  Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

Authors:  Noelle Asmar; Tony Ibrahim; Jean-François Rey
Journal:  Dig Dis Sci       Date:  2018-09       Impact factor: 3.199

Review 2.  Targeting immune checkpoints in breast cancer: an update of early results.

Authors:  Cinzia Solinas; Andrea Gombos; Sofiya Latifyan; Martine Piccart-Gebhart; Marleen Kok; Laurence Buisseret
Journal:  ESMO Open       Date:  2017-11-14

Review 3.  Tuning cancer fate: the unremitting role of host immunity.

Authors:  B Calì; B Molon; A Viola
Journal:  Open Biol       Date:  2017-04       Impact factor: 6.411

Review 4.  Intestinal microbiota: a new force in cancer immunotherapy.

Authors:  Zhujiang Dai; Jingqiu Zhang; Qi Wu; Huiwen Fang; Chunfeng Shi; Zhen Li; Chaobiao Lin; Dong Tang; Daorong Wang
Journal:  Cell Commun Signal       Date:  2020-06-10       Impact factor: 5.712

Review 5.  Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy.

Authors:  Yilun Liu; Zhongmin Li; Yuanyu Wu; Xiabin Jing; Lin Li; Xuedong Fang
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

Review 6.  Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.

Authors:  Yoshiaki Yura; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

7.  Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.

Authors:  Ariel E Marciscano; Joshua M Walker; Heather M McGee; Michelle M Kim; Charles A Kunos; Arta M Monjazeb; Stephen L Shiao; Phuoc T Tran; Mansoor M Ahmed
Journal:  J Immunother Cancer       Date:  2018-01-29       Impact factor: 13.751

Review 8.  Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.

Authors:  Yiming Wang; Rena Ma; Fang Liu; Seul A Lee; Li Zhang
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

Review 9.  Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy.

Authors:  Xiang Zhang; Qiaofei Liu; Quan Liao; Yupei Zhao
Journal:  J Cancer       Date:  2020-02-20       Impact factor: 4.207

Review 10.  Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.

Authors:  Eiko Hayase; Robert R Jenq
Journal:  Genome Med       Date:  2021-06-23       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.